The FDA isn’t the only hurdle for Novartis’ forthcoming CAR-T therapy, which could be the world’s first. There’s pricing and access, too. Drugs in this new class of one-time treatments are expected to be ultra-expensive, so the company is working up pricing and payment strategies now.
More: How will Novartis price its groundbreaking CAR-T med? R&D exec offers some clues